指南与共识其他结缔组织病

抗MDA5阳性皮肌炎相关快速进展型间质性肺病的治疗推荐

Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.
指南 / 共识 · Semin Arthritis Rheum · 2020-06-01

该指南针对抗黑色素瘤分化相关基因5(MDA5)阳性皮肌炎相关快速进展型间质性肺病(RPILD),由风湿病学、重症医学、肺病学、免疫学和内科学专家组成的工作组,基于截至2018年4月的系统文献综述(134项研究)制定。推荐初始联合免疫抑制治疗,首选大剂量糖皮质激素联合钙调神经磷酸酶拮抗剂(联用或不联用环磷酰胺);在禁忌或治疗失败时可个体化调整;血浆置换、多粘菌素B血液灌流和/或静脉注射免疫球蛋白可作为挽救选项;ECMO用于危及生命的情况。共形成13条推荐。

要点

  • 初始治疗推荐大剂量糖皮质激素联合钙调神经磷酸酶拮抗剂,联用或不联用环磷酰胺。
  • 钙调神经磷酸酶拮抗剂禁忌或治疗失败时,可个体化换用或加用其他免疫抑制剂。
  • 血浆置换、多粘菌素B血液灌流和/或静脉注射免疫球蛋白可作为挽救治疗。

核心结论

  • 基于134项研究的证据和专家意见,形成了13条关于抗MDA5阳性皮肌炎相关RPILD治疗的推荐。
  • 初始联合免疫抑制治疗获得普遍共识,首选大剂量糖皮质激素联合钙调神经磷酸酶拮抗剂(联用或不联用环磷酰胺)。

研究设计与样本

  • 工作组由风湿病学、重症医学、肺病学、免疫学和内科学专家组成,分两阶段识别关键领域并基于文献综述制定推荐。
  • 系统检索PubMed(MEDLINE)、EMBASE和Cochrane Library(Wiley Online)截至2018年4月的英文、西班牙文或法文文献,最终纳入134项符合标准的研究。

主要发现

  • 共134项研究构成免疫抑制治疗及辅助治疗的证据基础。
  • 专家对初始联合免疫抑制治疗总体达成共识,首选大剂量糖皮质激素联合钙调神经磷酸酶拮抗剂(联用或不联用环磷酰胺)。
  • 钙调神经磷酸酶拮抗剂禁忌或治疗失败时,可个体化换用或加用其他免疫抑制剂。
  • 血浆置换、多粘菌素B血液灌流和/或静脉注射免疫球蛋白可作为挽救选项。
  • 危及生命的情况可考虑ECMO,等待临床反应或作为肺移植桥接。

关键数值与推荐

  • 推荐初始使用联合免疫抑制治疗,首选大剂量糖皮质激素联合钙调神经磷酸酶拮抗剂(联用或不联用环磷酰胺)。
  • 钙调神经磷酸酶拮抗剂禁忌或治疗失败时,可个体化换用或加用其他免疫抑制剂。
  • 血浆置换、多粘菌素B血液灌流和/或静脉注射免疫球蛋白可作为挽救治疗选项。
  • 危及生命时可考虑ECMO,等待临床反应或作为肺移植桥接。

临床怎么用

  • 临床面对抗MDA5阳性皮肌炎相关RPILD患者,应初始采用大剂量糖皮质激素联合钙调神经磷酸酶拮抗剂(联用或不联用环磷酰胺)的联合免疫抑制方案。
  • 出现钙调神经磷酸酶拮抗剂禁忌或治疗失败时,需个体化调整免疫抑制剂方案。
  • 对难治或危重患者,可考虑血浆置换、多粘菌素B血液灌流和/或静脉注射免疫球蛋白作为挽救治疗。
  • 危及生命时评估使用ECMO,作为等待临床反应或肺移植的桥接措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The study aimed to develop evidence-based recommendations for the treatment of rapidly progressive interstitial lung disease (RPILD) associated with the anti-Melanoma Differentiation-Associated Gene 5-positive dermatomyositis (DM) syndrome. METHODS: The task force comprised an expert panel of specialists in rheumatology, intensive care medicine, pulmonology, immunology, and internal medicine. The study was carried out in two phases: identifying key areas in the management of DM-RPILD syndrome and developing a set of recommendations based on a review of the available scientific evidence. Four specific questions focused on different treatment options were identified. Relevant publications in English, Spanish or French up to April 2018 were searched systematically for each topic using PubMed (MEDLINE), EMBASE, and Cochrane Library (Wiley Online). The experts used evidence obtained from these studies to develop recommendations. RESULTS: A total of 134 studies met eligibility criteria and formed the evidentiary basis for the recommendations regarding immunosuppressive therapy and complementary treatments. Overall, there was general agreement on the initial use of combined immunosuppressive therapy. Combination of high-dose glucocorticoids and calcineurin antagonists with or without cyclophosphamide is the first choice. In the case of calcineurin antagonist contraindication or treatment failure, switching or adding other immunosuppressants may be individualized. Plasmapheresis, polymyxin B hemoperfusion and/or intravenous immunoglobulins may be used as rescue options. ECMO should be considered in life-threatening situations while waiting for a clinical response or as a bridge to lung transplant. CONCLUSIONS: Thirteen recommendations regarding the treatment of the anti-MDA5 positive DM-RPILD were developed using research-based evidence and expert opinion.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020. PMID: 32534273. doi:10.1016/j.semarthrit.2020.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。